Accessible version of data for Figure 1
Figure 1 shows the four situations presented to GPs and percentages of GPs who selected the desired response, as per COPD guidelines, of ‘FEV1 < 50% predicted and the patient has experienced two or more exacerbations in the previous year’.
The proportion of GPs who selected the desired response significantly increased after the educational visits, from 52% to 62% (p = 0.015).
Table for Figure 1: GP selection of a situation when they would prescribe an ICS + LABA fixed-dose combination
| GP response | GP responses before visit | GP responses after visit |
|---|---|---|
| When FEV1 < 50% predicted and the patient has experienced two or more exacerbations in the previous year | 52% | 62% |
| In a symptomatic patient regardless of the FEV1 value | 25% | 20% |
| When FEV1 < 50% predicted and the patient has experienced one exacerbation in the previous year | 17% | 15% |
| I would not consider prescribing an ICS + LABA fixed-dose combination in patients with COPD | 6% | 4% |
Accessible version of data for Figure 2
Figure 2 shows the percentages of GPs who reported the desired response when they were asked the survey question about controlling Marie’s symptoms. In line with COPD guidelines, the desired response was ‘step-up therapy to a combination LABA + LAMA’ inhaled medicine.
The proportion of GPs who selected the desired response significantly increased after the educational visits, from 67% to 78%.
Table for Figure 2: GP responses when asked about controlling Marie’s symptoms
| GP response | GP responses before visit | GP responses after visit |
|---|---|---|
| Step-up therapy to a combination LABA + LAMA | 67% | 78% |
| Step-up therapy to an ICS + LABA fixed-dose combination | 20% | 9% |
| Prescribe an additional ICS inhaler | 9% | 7% |
| Switch from a LAMA to a LABA | 3% | 4% |
| No action necessary | 1% | 2% |